Literature DB >> 23175466

Constitutive Notch2 signaling induces hepatic tumors in mice.

Michael T Dill1, Luigi Tornillo, Thorsten Fritzius, Luigi Terracciano, David Semela, Bernhard Bettler, Markus H Heim, Jan S Tchorz.   

Abstract

UNLABELLED: Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCC) are the most common liver tumors and a leading cause for cancer-related death in men. Notch2 regulates cellular differentiation in the developing and adult liver. Although aberrant Notch signaling is implicated in various cancers, it is still unclear whether Notch2 regulates proliferation and differentiation in liver carcinogenesis and thereby contributes to HCC and CCC formation. Here, we investigated the oncogenic potential of constitutive Notch2 signaling in the liver. We show that liver-specific expression of the intracellular domain of Notch2 (N2ICD) in mice is sufficient to induce HCC formation and biliary hyperplasia. Specifically, constitutive N2ICD signaling in the liver leads to up-regulation of pro-proliferative genes and proliferation of hepatocytes and biliary epithelial cells (BECs). Using the diethylnitrosamine (DEN) HCC carcinogenesis model, we further show that constitutive Notch2 signaling accelerates DEN-induced HCC formation. DEN-induced HCCs with constitutive Notch2 signaling (DEN(N2ICD) HCCs) exhibit a marked increase in size, proliferation, and expression of pro-proliferative genes when compared with HCCs from DEN-induced control mice (DEN(ctrl) HCCs). Moreover, DEN(N2ICD) HCCs exhibit increased Sox9 messenger RNA (mRNA) levels and reduced Albumin and Alpha-fetoprotein mRNA levels, indicating that they are less differentiated than DEN(ctrl) HCCs. Additionally, DEN(N2ICD) mice develop large hepatic cysts, dysplasia of the biliary epithelium, and eventually CCC. CCC formation in patients and DEN(N2ICD) mice is accompanied by re-expression of hepatocyte nuclear factor 4α(HNF4α), possibly indicating dedifferentiation of BECs.
CONCLUSION: Our data establish an oncogenic role for constitutive Notch2 signaling in liver cancer development.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23175466     DOI: 10.1002/hep.26165

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  58 in total

1.  Combination of sorafenib and Valproic acid synergistically induces cell apoptosis and inhibits hepatocellular carcinoma growth via down-regulating Notch3 and pAkt.

Authors:  Wanhu Zhu; Qing Liang; Xu Yang; Yan Yu; Xiaoying Shen; Guangchun Sun
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

Review 2.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

3.  A cell-surface β-hydroxylase is a biomarker and therapeutic target for hepatocellular carcinoma.

Authors:  Arihiro Aihara; Chiung-Kuei Huang; Mark J Olsen; Qiushi Lin; Waihong Chung; Qi Tang; Xiaoqun Dong; Jack R Wands
Journal:  Hepatology       Date:  2014-08-25       Impact factor: 17.425

Review 4.  Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases.

Authors:  Luca Fabris; Romina Fiorotto; Carlo Spirli; Massimiliano Cadamuro; Valeria Mariotti; Maria J Perugorria; Jesus M Banales; Mario Strazzabosco
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-08       Impact factor: 46.802

Review 5.  Emerging concepts in biliary repair and fibrosis.

Authors:  Luca Fabris; Carlo Spirli; Massimiliano Cadamuro; Romina Fiorotto; Mario Strazzabosco
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-05-19       Impact factor: 4.052

6.  Sox9 Is a Modifier of the Liver Disease Severity in a Mouse Model of Alagille Syndrome.

Authors:  Joshua M Adams; Kari A Huppert; Eumenia C Castro; Mario F Lopez; Nima Niknejad; Sanjay Subramanian; Neda Zarrin-Khameh; Milton J Finegold; Stacey S Huppert; Hamed Jafar-Nejad
Journal:  Hepatology       Date:  2020-01-24       Impact factor: 17.425

7.  Differential effects of targeting Notch receptors in a mouse model of liver cancer.

Authors:  Erik G Huntzicker; Kathy Hötzel; Lisa Choy; Li Che; Jed Ross; Gregoire Pau; Neeraj Sharma; Christian W Siebel; Xin Chen; Dorothy M French
Journal:  Hepatology       Date:  2015-01-28       Impact factor: 17.425

Review 8.  Cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Lancet       Date:  2014-02-26       Impact factor: 79.321

9.  miR-21 Inhibition Reduces Liver Fibrosis and Prevents Tumor Development by Inducing Apoptosis of CD24+ Progenitor Cells.

Authors:  Jing Zhang; Jingjing Jiao; Silvia Cermelli; Kyle Muir; Kwang Hwa Jung; Ruhai Zou; Asif Rashid; Mihai Gagea; Sonya Zabludoff; Raghu Kalluri; Laura Beretta
Journal:  Cancer Res       Date:  2015-03-13       Impact factor: 12.701

Review 10.  Emerging roles of Notch signaling in liver disease.

Authors:  Fabian Geisler; Mario Strazzabosco
Journal:  Hepatology       Date:  2014-09-19       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.